ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.
Last trade$1.15
Day change-$0.03 (-2.54%)
Day range$1.13 – $1.23
Volume949,722
Market cap$167M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for PRQR.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for PRQR.
Recent news
Company coverage with links to the original publishers.
ProQR Therapeutics announced upcoming presentations of its Axiomer RNA editing platform at major conferences including TIDES Europe, AASLD The Liver Meeting 2026, and Nature Conferences RNA at the Bench and Bedside V. The company will showcase clinical data from its Phase 1 AX-0810 study demonstrating favorable safety and target engagement, as well as preclinical data for next-generation candidate AX-0811, with initial Phase 1 data expected in early January 2027.
ProQR Therapeutics announced the nomination of Dr. Lykke Hinsch Gylvin, Chief Medical Officer at Boehringer Ingelheim, to its Board of Directors. Dr. Gylvin brings over 20 years of pharmaceutical leadership experience from roles at Boehringer Ingelheim, Novartis, AstraZeneca, Roche, Novo Nordisk, and Lundbeck. The nomination will be submitted for shareholder approval at the upcoming Annual General Meeting.
ProQR Therapeutics announced pipeline expansion with multiple clinical programs advancing toward the clinic. The company's lead program AX-0810 is on track to report target engagement data in H1 2026, with biliary atresia selected as the initial Phase 2 indication. Additional programs AX-0811, AX-0422, and AX-2911 are progressing with anticipated CTA filings and clinical data readouts expected through 2027. ProQR expects to deliver multiple clinical data readouts within its current cash runway extending into mid-2027.
ProQR Therapeutics reported €92.4 million in cash at year-end 2025 and advanced its lead program AX-0810 into Phase 1 testing for cholestatic diseases, with target engagement data expected in H1 2026. The company selected development candidates AX-2402 for Rett syndrome and AX-2911 for MASH, achieved $4.5 million in Eli Lilly collaboration milestones, and projects cash runway into mid-2027. R&D costs increased to €44.7 million and net loss widened to €42.2 million for 2025.
ProQR Therapeutics will participate in the 8th Annual Evercore Healthcare Conference, presenting its Axiomer™ RNA editing technology platform that enables targeted single nucleotide changes in RNA to potentially develop new disease treatments.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.